Patch test results from the Mayo Clinic Contact Dermatitis Group, 1998-2000

Wetter, David A.; Davis, Mark D.P.; Yiannias, James A.; Cheng, Janet F.; Connolly, Suzanne M.; el-Azhary, Rokea A.; Farmer, Sara A.; Fett, Debra D.; Johnson, Janis S.; Linehan, Diane L. Nordberg; Richardson, Donna M.; Schroeter, Arnold L.

doi:10.1016/j.jaad.2005.04.077

Cited by 94 publications

(55 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…20,21 Both the Mayo Clinic and North American Contact Dermatitis Group reported patch-test positive rates of less than 3% for tixocortol pivalate and of 1.6% for budesonide in a general patch-test population. 20,21 Similarly low reaction rates for topical corticosteroids have been found in patch-test studies focusing on vulval dermatoses. 2,3 Considering the widespread use of topical corticosteroids to irritated and inflamed skin and mucous membranes, it is reassuring that true allergic contact sensitivity appears to be relatively rare.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective study of patch testing in patients with vulval pruritus

et al. 2008

View full text Add to dashboard Cite

SUMMARYForty-three patients with the primary complaint of vulval pruritus were recruited to take part in this prospective patch-testing study. A detailed questionnaire was administered to each and patch testing to an extended battery of allergens was undertaken. This included the European standard series, preservatives, corticosteroids and a battery of common over-the-counter topical vulval treatments. Analysis of demographic data and prior treatments used, and various other parameters, were studied in the context of patch-test results. This prospective study reports a very high rate of contact sensitivity in patients presenting with vulval pruritus, with 81.4% of those tested having at least one contact allergen detected. One or more clinically relevant allergens were found in 44% of the subjects patch tested. The variables found to predict a greater likelihood of a contact allergy were a biopsy diagnosis of vulval dermatitis, the use of multiple topical treatments, sexual inactivity and patients with severe pruritus on a selfreported scale. Most importantly, many clinically relevant allergens these patients reacted to were outside the European standard series. This highlights the need for an extended series in this patient population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prospective study of patch testing in patients with vulval pruritus

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Níquel es por excelencia el alérgeno de contacto más frecuente y prevalente en todos los estudios a nivel mundial 17,18,22,23,24,25,26 como también lo es en nuestro estudio. Tiene una frecuencia de 34,28% en mujeres, siendo la más alta del género.…”

Section: Mezcla De Fragancias 14unclassified

Reactividad y evolución de 4.022 tests de parche en dermatitis de contacto realizadas entre 1995 y 2011 en Santiago de Chile

et al. 2015

View full text Add to dashboard Cite

“…In general, patients were not patch tested if they applied topical corticosteroids to potential patch test sites; took immunosuppressive drugs, including oral corticosteroids; or had medical conditions that could compromise the evaluation of skin responsiveness. 10,11 Information on patient demographics, characteristics of the devices, reasons for patch testing, and patch test results was extracted from the clinical database and clinical records. This study was approved by the Mayo Clinic institutional review board.…”

Section: Patientsmentioning

confidence: 99%